Search

Ticagrelor is one of the main antiplatelet drugs used for prevention of coronary blood clots after interventional procedures in patients with acute coronary syndromes. It has previously been shown that gene variants of

Aims To compare the safety and efficacy of edoxaban combined with P2Y12 inhibition following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) presenting with an acute coronary syndrome (ACS) or chronic coronary syndrome (CCS). Methods and results In this pre-specified sub-analysis of the ENTRUST-AF PCI trial, participants were randomly assigned 1:1 to edoxaban- or vitamin K antagonist (VKA)-based strategy and randomization was stratified by ACS (edoxaban n = 388, VKA n = 389) vs. CCS (edoxaban n = 363, VKA = 366). Participants received edoxaban 60 mg once-daily plus a P2Y12 inhibitor for 12 months, or VKA combined with a P2Y12 inhibitor and aspirin 100 mg (for 1-12 months). The primary bleeding endpoint at 12 months occurred in 59 (15.2%) vs. 79 (20.3%) ACS patients [hazard ratio (HR): 0.73, 95% confidence interval (CI): 0.59-1.02, P = 0.063], and in 69 (19.0%) vs. 73 (19.9%) CCS patients (HR: 0.94, 95%CI: 0.68-1.31, P = 0.708) with edoxaban- and VKA-based therapy, respectively [P for interaction (P-int) = 0.2741]. The main secondary endpoint (composite of CV death, myocardial infarction, stroke, systemic embolic events, or definite stent thrombosis) in ACS patients was 33 (8.5%) vs. 28 (7.2%) (HR: 1.16, 95%CI: 0.70-1.92), compared with 16 (4.4%) vs. 18 (4.9%) (HR: 0.91, 95%CI: 0.47-1.78) CCS patients with edoxaban and VKA-based therapy, respectively (P-int = 0.5573). Conclusions In patients with AF who underwent PCI, the edoxaban-based regimen, as compared with VKA-based regimen, provides consistent safety and similar efficacy for ischaemic events in patients with AF regardless of their clinical presentation. This work was supported and funded by Daiichi Sankyo. Vranckx, P (corresponding author), Hasselt Univ, Fac Med & Life Sci, Dept Cardiol & Crit Care Jessaziekenhuis Hasselt, Hasselt, Belgium. pascal.vranckx@iccuhasselt.be

Objectives: Recanalisation of chronic total occlusions (CTOs) in interventional cardiology is one of the most challenging and complex procedures. Currently, no data are available about the impact of BMI on success rates among CTO patients undergoing percutaneous coronary intervention. The aim of this study was to investigate the impact that BMI has on success rates, complications, and procedure characteristics among a large group of CTO patients who underwent percutaneous coronary intervention. Methods: The present study retrospectively included 420 patients who underwent percutaneous coronary intervention for at least one chronic total occlusion in the Hospital of the Lithuanian University of Health Sciences of Kaunas. All patients were grouped by their BMI level based on the World Health Organisation classification. Statistical analyses were performed using SPSS 20.0 software. The value of p 0.05). Conclusion: This retrospective study indicates that BMI has no impact on in-hospital outcomes in patients with chronic total occlusion after percutaneous coronary intervention.

Patients with STEMI undergoing primary percutaneous coronary intervention (PPCI) frequently have suboptimal platelet inhibition in the early hours after the ticagrelor loading dose. It has been hypothesized that early loading dose administration optimizes platelet inhibition in PPCI and, therefore

Advances in stenting technology and procedural technique are changing the role of percutaneous coronary intervention (PCI) in the treatment of left main coronary artery (LMCA) disease. The location of the lesion in LMCA has a great influence on the stenting strategy. In many cases, the length of the

Inflammation plays a key role in the process of the formation of the atherosclerosis and in the pathogenesis of acute coronary syndrome. Myocardial necrosis induces the release of proinflammatory markers. It may even lead to tissue damage and eventually to the development of undesirable events such

Bifurcation percutaneous coronary intervention (PCI) remains a challenging frontier in interventional cardiology. In percutaneous coronary intervention for de novo coronary non-left main bifurcation lesions, the optimal technique for stenting is still a matter of discussion. We sought to determine